Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care by Ali, Mahmood et al.
Ali, Mahmood and Grogan, Sarah and Powell, Sue and Staniford, Leanne
and Nazir, Jameel and Landeira, Margarita and Covernton, Patrick JO and
Jaggi, Ashley and Fatoye, Francis and Holt, Maxine (2019)Qualitative Anal-
ysis of Factors Influencing Patient Persistence and Adherence to Prescribed
Overactive Bladder Medication in UK Primary Care. Advances in Therapy.
ISSN 0741-238X
Downloaded from: http://e-space.mmu.ac.uk/624135/
Version: Published Version
Publisher: Springer Science and Business Media LLC
DOI: https://doi.org/10.1007/s12325-019-01098-y
Usage rights: Creative Commons: Attribution-Noncommercial 4.0
Please cite the published version
https://e-space.mmu.ac.uk
ORIGINAL RESEARCH
Qualitative Analysis of Factors Influencing Patient
Persistence and Adherence to Prescribed Overactive
Bladder Medication in UK Primary Care
Mahmood Ali . Sarah Grogan . Sue Powell . Leanne Staniford .
Jameel Nazir . Margarita Landeira . Patrick J. O. Covernton .
Ashley Jaggi . Francis Fatoye . Maxine Holt
Received: June 18, 2019
 The Author(s) 2019
ABSTRACT
Introduction: Pharmacotherapy for overactive
bladder (OAB) is generally associated with low
rates of persistence and adherence. This study
was conducted to explore the patient journey in
a UK primary care setting (experiences, percep-
tions, attitudes, and levels of engagement and
expectations) and identify self-reported reasons
for patient non-adherence and/or non-persis-
tence to medications for OAB.
Methods: This was a qualitative, non-interven-
tional study involving one-to-one semi-struc-
tured, face-to-face or phone interviews with
individuals aged 40–80 years, diagnosed with
OAB, and currently taking, or having taken,
either antimuscarinic or b3-adrenoceptor ago-
nist medications within the last 12 months.
Thematic analyses of interview transcripts
identified themes surrounding the participants’
experiences with OAB.
Results: A total of 20 interviews were con-
ducted (face-to-face, n = 13; telephone, n = 7).
Interviews from five men and 13 women (mean
age 70 years) were included in the final analysis.
The most common OAB symptoms reported
included urgency, frequency, incontinence and
nocturia. Several key themes of factors influ-
encing persistence and/or adherence to pre-
scribed OAB medication were identified:
patients’ attitude and condition adaptation
behaviour; support with treatment; unmet effi-
cacy/tolerability expectations; drug/condition
hierarchy. Non-adherence and/or non-persis-
tence to OAB medication was largely inten-
tional, with patients balancing side effects
against perceived clinical benefits. Perceived
lack of efficacy was the primary reason for dis-
continuing treatment. Other factors cited
included side effects of medication (either
experienced or a fear of future effects), a general
aversion to long-term medication taking,
drug/condition hierarchy relative to other
comorbidities, and limited healthcare profes-
sional (HCP) support/engagement. Patients
expressed condition adaptation behaviours to
help self-manage their condition.
Conclusion: Persistence and adherence to OAB
medication may be suboptimal. HCPs might be
able to improve persistence and adherence by
fostering realistic treatment expectations and
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scheduling regular medication reviews. These
measures may help optimise patient care and
support more adherent behaviours, thus min-
imising the impact of undertreated OAB on
patient quality of life.
Funding: Innovate UK and Astellas Pharma
Europe Ltd (APEL).
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INTRODUCTION
Overactive bladder (OAB) is a common, dis-
tressing and often chronic condition charac-
terised by urinary urgency, usually
accompanied by increased daytime frequency
and/or nocturia, with or without urinary
incontinence, in the absence of urinary tract
infection or other detectable disease [1]. OAB is
common in both men and women, with
approximately 546 million adults worldwide
(10.9%) estimated to be affected by OAB in 2018
[2]. The prevalence of OAB increases with
advancing age [3–5], and OAB is expected to
become more common in the UK because of an
increasingly ageing population [6]. OAB
adversely affects health-related quality of life
(HRQoL), including emotional, sexual and work
productivity impacts [7, 8]. Individuals with
OAB express anxiety, fear of incontinence, a
sense of depression and hopelessness associated
with their condition [9].
Behavioural and lifestyle modifications are
the initial management strategies recom-
mended for OAB [10]. Pharmacotherapy is rec-
ommended if symptom management through
these conservative measures is ineffective.
Pharmacotherapy includes antimuscarinic
agents or the b3-adrenoceptor agonist mirabe-
gron (a second drug in this class is only avail-
able in Japan) [10, 11]. As OAB can be chronic
and is often progressive, patients may need to
continue with treatment for lasting symptom
relief [12].
Despite the considerable HRQoL impact of
OAB, individuals are often reluctant to consult a
healthcare professional (HCP) about their con-
dition [9, 13]. Among those who seek treat-
ment, low rates of persistence and/or adherence
with pharmacotherapy are evident, especially
for antimuscarinic agents. A systematic litera-
ture review of real-world data in OAB reported
1-year persistence rates of 12–25% and 32–38%
for antimuscarinic agents and mirabegron,
respectively [14]. Median time to discontinua-
tion was less than 5 months for antimuscarinic
agents (except one study, 6.5 months [15]) and
5.6–7.4 months for mirabegron [14]. A UK
Clinical Practice Research Datalink retrospective
study [16] found that median time to discon-
tinuation of antimuscarinic agents was
1.0–2.6 months compared with 5.6 months for
mirabegron.
Non-adherence and/or non-persistence to
pharmacological treatment has a major impact
on health outcomes and healthcare resource
utilisation, especially for long-term conditions
such as OAB [7, 14, 17–21]. While a number of
studies have explored persistence and/or
adherence to OAB medications, the patients’
perspectives and the reasons for discontinuing
or not starting treatment have not been exam-
ined comprehensively. Identification of the
reasons for non-adherence and/or non-persis-
tence would provide insights to enable the
development of measures to support long-term
treatment goals. The objectives of this study
were to explore patient treatment, experiences,
perceptions, attitudes, and levels of engagement
and expectations; and identify self-reported
reasons for patient non-adherence and/or non-
persistence to medications for OAB in a UK
primary care setting.
METHODS
Study Design
This was a qualitative, non-interventional study
involving one-to-one interviews. Participants
were required to meet the predetermined
inclusion criteria: men or women aged
40–80 years; diagnosed with OAB; fluent in
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English; and currently taking, or having taken,
either antimuscarinic agents or b3-adrenoceptor
agonists for OAB within the last 12 months.
Individuals with memory impairment, cogni-
tive decline or dementia (as documented within
medical records) were not eligible for inclusion.
Two UK National Health Service Research and
Development sites (covering Kent, Surrey, and
Sussex; and Greater Manchester) invited pri-
mary care practices (PCPs) from these regions to
participate in this study. PCPs were sent the
study protocol, copies of the patient informa-
tion sheet, a study poster to display in the
practice, and a research information sheet for
practices form to help them decide whether
they were able to participate in this study.
Participating PCPs compiled lists of their reg-
istered patients with OAB and applied the study
inclusion and exclusion criteria. An HCP from
each of the PCPs then reviewed the list of poten-
tial participants to confirm that those who pro-
gressed to be invited to participate in the study
were appropriate to do so (correctly coded OAB,
not suffered recent bereavement/terminally ill,
etc.). Invitation packs were posted to the home
address of eligible participants. This included an
information sheet outlining the area of research
and rationale (Supplementary Appendix A). Par-
ticipants who returned consent-to-be-contacted
forms were telephoned by the study team to reit-
erate the purpose of the research, confirm their
consent to take part in this study, and to arrange
interviews. This study has gone through a health
research authority and ethics review with NW
Liverpool East REC (Central Manchester is the
lead Research & Development site). IRAS project
ID 198502. All participants provided their written
consent to take part in this study.
Interviews
Semi-structured interviews were conducted
face-to-face or over the telephone by L.S., a
research associate with more than 5 years’
experience in qualitative research. A reflective
journal recorded by the interviewer detailed
that this was not a familiar topic of research,
thus interviews were initiated with no preset
assumptions or bias regarding medication
persistence and/or adherence in relation to
OAB. Participants were briefed on the inter-
viewer’s research experience and the purpose of
the interviews prior to the interview com-
mencing; they were also made aware that the
interviewer had no commercial interests related
to the study. Interviews were designed to take
approximately 1 h and followed a discussion
guide (see Supplementary Appendix B). They
were conducted in participants’ homes (Greater
Manchester) and over the telephone (Kent,
Surrey, and Sussex). Presence of non-partici-
pants (i.e. partners/family members) was at the
discretion of the participants. Each interview
was voice recorded and notes taken. Partici-
pants received a £10 store voucher upon inter-
view completion. Participants had no further
involvement following the interviews and
repeat interviews were not performed.
The discussion guide was produced by aca-
demic researchers with expertise in qualitative
research methods, with input from subject
matter experts. Questions were framed to elicit
full responses and obtain a narrative of the
patient journey in their own words: starting
with OAB history and coping strategies, inter-
actions with their HCPs, treatment history, and
treatment expectations; following up with a
discussion of their strategies for adherence and
finally the opportunity for any further com-
ments (Supplementary Appendix B).
Analyses
Interviews were transcribed verbatim (by M.A.).
A sample of transcripts (3/18 transcripts; 17%)
was reviewed against corresponding recordings
by the Chief Investigator (M.H.) to ensure
completeness and accuracy of the transcripts. In
addition, an academic Health Psychologist
(S.G.), with more than 20 years’ experience of
conducting and publishing qualitative research,
performed a validation crosscheck of the
resulting themes.
Transcribed data were collectively analysed,
using NVivo Pro 11 software (QSR Interna-
tional, Warrington, UK), to identify a set of
themes on the basis of the method of thematic
analysis by Braun and Clarke [22]. Data
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collection and analysis were discontinued when
data saturation was achieved (i.e. no new
information was discovered) [23]. Identified
themes were agreed by all authors.
RESULTS
Study Size
Of the 199 invitation packs sent, 27 positive
responses were received and 7 respondents were
excluded (Fig. 1). A total of 20 interviews were
conducted (face-to-face, n =13; telephone,
n =7), between June and August 2018. Subse-
quently, two interviews were excluded because
of poor-quality recordings not allowing accu-
rate transcription and analysis. Upon tran-
scribing and analysing the data from the 18
interviews, the study team recognised that sat-
uration had been reached.
Participant Demographics
Interviews from five men and 13 women, with
an overall mean age of 70 years (range 57–80),
were included in the final analysis (Table 1). The
most common OAB symptoms reported inclu-
ded urgency, frequency, incontinence and
nocturia.
Factors Influencing Persistence and/
or Adherence to Prescribed OAB
Medication
Several key themes of factors influencing per-
sistence and/or adherence to prescribed OAB
medication were identified, broadly categorised
into four subgroups: patients’ attitude and
condition adaption behaviour; support with
treatment; discontinuing treatment; drug/con-
dition hierarchy (Fig. 2).
Patients’ Attitude to Medication
and Condition Adaptation Behaviour
Some participants questioned the necessity of
taking medication and balanced the perceived
risks (side effects) against the clinical benefits in
their decisions to start or continue taking OAB
medication—‘If it is necessary to take the med-
ication, then it should be taken as long as there
are no noticeable side effects’, (participant #16).
Other participants (#7, 8 and 17) expressed that
they would take medication if there were tan-
gible benefits (improvement in OAB symp-
toms). However, one participant (#7) would
advise others against starting OAB medication,
despite experiencing some symptom relief, due
to a side effect (headache) that led to their non-
adherence.
Negative beliefs regarding risk of side effects
were the basis of one participant’s (#13) deci-
sion to only take OAB medication on an ‘as-
needed’ basis, despite a conviction that regular
usage would be beneficial, while another par-
ticipant (#10) was reluctant to accept a dose
increase of OAB medication, although
acknowledging it might improve symptoms.
One participant (#5) chose not to be exposed to
any potential danger from side effects/compli-
cations, on the basis of a prior hospitalisation
following an incorrect prescription for
hypertension.
Non-adherence was largely intentional (e.g.
participants did not forget to take their
Fig. 1 Summary of patient recruitment and participation
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medication). One participant (#2) distinguished
between their OAB medication, which they had
decided not to take, and their other daily med-
ications that they continued to take. Descrip-
tors from participants in reference to
remembering to take medication included ‘no
challenges at all’ (participant #17) and ‘auto-
matic’ (participant #8). Strategies for avoiding
non-intentional adherence included incorpo-
rating medicine taking into a daily routine (e.g.
taking tablets with breakfast or just before going
to bed); keeping medication in conspicuous
places and in the line of sight; and using dosset
boxes. Although these strategies were highly
effective, they were not without certain chal-
lenges e.g. if the usual schedule was disrupted
by a change in location or setting. One
participant (#9), who described a routine of
taking medication around breakfast time, stated
that adherence would be difficult if a new
medication was prescribed that needed to be
taken at a different time of the day.
Participants modified their daily behaviours
and planned ahead in order to foster a sense of
safety and confidence, including keeping an
acute awareness of toilet locations, using the
toilet pre-emptively, and gravitating towards
familiar places, such as their own home, where
others would not witness or be affected by their
symptoms. Among female participants, absor-
bent pads were commonly used as a precau-
tionary measure. Several participants described
variants of ‘planning your day around being
near a toilet’ and ‘life around toilets’. This was a
Table 1 Study participants demographic and background information
Area Participant number Sex Age (years) Main OAB symptoms
Greater Manchester 1 M 64 Urgency, incontinence
2 F 66 Urgency, incontinence, nocturia
3 F 58 Frequency, urgency, incontinence
4 F 69 Urgency, incontinence
5 F 71 Frequency, urgency
6 F 57 Frequency, nocturia, incontinence
7 F 70 Frequency, urgency, high volume
8 F 77 Frequency
9 F 80 Incontinence, urgency
10 F 58 Urgency, nocturia, incontinence
11 F 78 Incontinence, urgency, nocturia
12 F 61 Frequency, incontinence,
high volume at night
13 M 65 Urgency, frequency
Kent, Surrey, and Sussex 14 M 78 Nocturia, urgency
15 F 80 Incontinence, nocturia, urgency
16 M 71 Urgency, incontinence, nocturia
17 F 67 Frequency, nocturia
18 M 70 Nocturia
F female, M male, OAB overactive bladder
Adv Ther
key element in the pursuit of feeling secure—
‘Sainsbury’s have got loos, so… if I need a loo,
I’m alright’ (participant #5). One participant
(#7) mentioned planning social interactions
specifically in places where they had knowledge
of the availability of public toilets. One partici-
pant (#6) described a reluctance to go on holi-
day—‘I haven’t been this year, ‘til I wanted to
sort me bladder out’, and being around people
they were comfortable with—‘In a friend’s
apartment, I’m safe… they know that I can’t
control’.
Some participants demonstrated a reluctance
to make recommended lifestyle modifications,
including two participants (#12 and 17) who
perceived difficulties/impracticalities of incor-
porating pelvic floor exercises into their rou-
tine, and another (#7) who did not adhere to
caffeine avoidance advice, as this entailed giv-
ing up a daily habit.
Support with Treatment
Several participants described a lack of formal
reviews for OAB medication, in contrast to
routine medication reviews conducted for their
other conditions. Some participants felt their
general practitioners (GPs) were ‘too busy’ to
conduct monitoring reviews. Reviews for OAB
were rushed or overlooked, and medicines that
caused specific problems were given
prominence during the review process, which
was focused on problem-solving, rather than
optimising their care. In other cases, repeat
prescriptions were issued without medication
reviews.
One participant (#16) mentioned that the
lack of their own reviews was due to a reluc-
tance to visit the GP, downplaying their own
needs against those of others who ‘really are ill’.
A lack of communication with the HCP, a
preference to avoid medication, and a doubted
OAB diagnosis were the reasons given by
another participant (#17) for not attending a
repeat visit after initially being prescribed a
1-month supply of OAB medication. One par-
ticipant (#13) decided to take OAB medication
sporadically to manage their inconsistent
symptoms, because the HCP appeared uninter-
ested and did not stress taking the tablets daily.
Although convinced that daily medication
would offer complete symptom relief, this was
tempered by a fear of unknown long-term
effects. However, some participants described
their GP as being supportive, providing invita-
tions for reviews and imparting confidence.
Unmet Efficacy/Tolerability Expectations
Over half of participants cited lack of efficacy as a
reason for non-adherence and/or non-persis-
tence of OAB medication (Table 2). One
Fig. 2 Identiﬁed themes from interviews on persistence and adherence to OAB medication
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participant (#14) expressed frustration due to
poor efficacy and the need to take sleeping pills to
counteract the secondary effects of next-day
fatigue from nocturia. According to many par-
ticipants, side effects further prompted their
decision to discontinue ineffective medication.
Reported side effects affecting persistence and/or
adherence included dry mouth and headaches.
Drowsiness was mentioned by several partici-
pants, but mostly in a positive context as an aid to
sleep (reducing the effects of nocturia). One
participant (#18), who initially experienced a
‘minor improvement’ in urinary symptoms from
a-blocker monotherapy, subsequently received
an add-on antimuscarinic agent, but did not
perceive any ‘great improvement’ from combi-
nation therapy. Together with the side effect of
dry mouth, this led to complete treatment dis-
continuation; this participant was still symp-
tomatic and waking several times a night. One
participant (#15) experienced a dull stomach
ache from a twice-daily antimuscarinic agent,
which resulted in once-daily treatment and
eventual discontinuation (advised by the HCP)
due to potential effects on memory. Subse-
quently, they were not offered an alternative
Table 2 Reasons for discontinuing OAB medication
Participant
number
Sex Age
(years)
Primary reasons for
discontinuation
Other reasons
1 M 64 Lack of efﬁcacy Tablet being ‘nothing special’
2 F 66 Side effects –
3 F 58 Did not discontinue –
4 F 69 Lack of efﬁcacy and requirement
for ECGs
Fear of unknown effects
5 F 71 Side effects Taking too many tablets
6 F 57 Waning efﬁcacy, side effects OnabotulinumtoxinA
7 F 70 Side effects Taking too many tablets
8 F 77 Lack of efﬁcacy Suspected side effect
9 F 80 Side effects Fear of unknown effects
10 F 58 Side effects Aversion to dose escalation, wanting to switch
medication
11 F 78 Did not discontinue –
12 F 61 Lack of efﬁcacy, side effects Unconvinced of OAB diagnosis (more a ‘weak
bladder’)
13 M 65 Fear of side effects Unclear instructions
14 M 78 Lack of efﬁcacy Side effects
15 F 80 Lack of efﬁcacy, side effects Surgery stopped the medication
because of potential cognitive effects
16 M 71 Lack of efﬁcacy, side effects Trial and error
17 F 67 Unclear instructions Pill aversion
18 M 70 Lack of efﬁcacy –
ECG electrocardiogram, F female, M male, OAB overactive bladder
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treatment and continued to experience the wax
and wane of OAB symptoms. b3-adrenoceptor
agonists were linked to a fear of future side effects
by another participant (#4) due to additional
blood pressure and electrocardiogram monitor-
ing required while on treatment.
Doubtful efficacy together with a suspicion
that the treatment was causing a deterioration
in eyesight led to one participant (#12) discon-
tinuing treatment. This perceived lack of effi-
cacy was further reinforced by an assessment of
the HCP’s demeanour (while initially prescrib-
ing the drug), interpreted as being ‘unsure
whether these tablets worked or not’. The par-
ticipant subsequently re-evaluated the side
effects of the medication, attributing the
decline in eyesight to advancing age instead,
which coincided with a renewed motivation to
control symptoms after taking up golf. They
remained adherent despite still doubting the
effectiveness of medication. Another partici-
pant (#10) was unsure as to which of their
medications were responsible for their symp-
toms of blurred vision and gastro-oesophageal
disturbances and intended to discontinue the
OAB medication to gauge how much of an
effect this might have. They also cited a lack of
awareness about the availability of a range of
medications for OAB as one of the reasons for
not returning to the GP to try a different drug—
‘I think from reading that form [patient infor-
mation sheet], there appears to be quite a lot of
different drugs for, the same problem. And my
GP didn’t offer me a choice or anything’.
Drug/Condition Hierarchy
Participants showed a general pill aversion,
choosing to discontinue OAB medication while
prioritising other conditions. For example, one
participant (#7) had discontinued several OAB
medications because of side effects and a wish to
avoid tablets where possible, while maintaining
adherence to hypertension medication and
letrozole, on the basis of the potentially serious
consequences of not doing so. This was echoed by
participant #16 who described adherence to
hypertension medication: ‘Oh I take those with-
out fail, because my blood pressure was quite
high’. Some participants chose to delay OAB
treatment until they could no longer endure the
symptoms and associated consequences. One
participant (#10) became more open to treatment
following a worsening of OAB, due to the effect of
their OAB symptoms on chronic migraines.
Conversely, the presence of comorbidities,
including liver disease culminating in a liver
transplant, was a driving factor in adherence to
OAB medication for one participant (#1), who
persisted with treatment despite lack of efficacy;
now on their third OAB medication (an
antimuscarinic agent), they were planning to
request a fourth. Nevertheless, theywere reluctant
to seek HCP advice specifically for OAB (despite
worsening of symptoms) and were delaying con-
sultation until another healthcare need arose.
When participants did consult their HCP
about their OAB, they often felt that the condi-
tion was regarded with low priority by the HCP.
According to one participant (#13), the HCP set
the tone of low importance of OAB and its
treatment by giving the impression of providing
a diagnosis and treatment to ‘get rid’ of the
patient when an ultrasound test did not reveal
any particular issue. This was compounded by
there being no review of OAB medication, with
the HCP supplying prescriptions only. One par-
ticipant (#3), who worked in a GP clinic, drew a
comparison between the relative prominence
given to conditions such as asthma and prostate
cancer against the dearth of information publicly
available for ‘day-to-day’ conditions, such as
OAB, which ‘really interfere with your lifestyle’.
This was mirrored by another participant’s (#12)
opinion that there is a lack of effort into devel-
oping OAB medication, as researchers focused on
the ‘big things’.
DISCUSSION
Non-adherence and non-persistence with treat-
ment are behaviours that feature prominently
among patients with OAB [24, 25]. Through
qualitative patient interviews, this study pro-
vides insights into the complex and individu-
alistic factors driving such behaviours in
patients who have undergone pharmacological
treatment for OAB.
The interviews uncovered several common
themes surrounding non-adherence and/or
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non-persistence of OAB medication. Failure to
take OAB medication was largely intentional,
with many participants making decisions on
the basis of a perceived balance of benefits and
risks and/or lifestyle choices. Unintentional
non-adherence was not identified as a problem,
as participants tended to alter their behaviour to
facilitate medicine taking. In this study, the
main reasons for treatment discontinuation, as
reported by participants, were, firstly, a per-
ceived lack of efficacy, resulting in unmet
treatment expectations and, secondly, experi-
ence of side effects (or fear of potential side
effects). There was also a general aversion to
taking chronic medication, as well as a ten-
dency to prioritise medications on the basis of
the perceived prominence of the condition and
the consequences of not taking the medication,
giving rise to a drug/condition hierarchy. Lack
of engagement and support from HCPs were
also factors that may have contributed to poor
treatment persistence for OAB.
Dry mouth was the most widely mentioned
side effect leading to discontinuation of OAB
medication, followed by headache and nau-
sea—effects typically associated with antimus-
carinic therapy and commonly cited as reasons
for treatment discontinuation [26, 27].
Improved rates of persistence and/or adherence
have been reported with the b3-adrenoceptor
agonist mirabegron compared with antimus-
carinic agents [16, 28, 29], perhaps owing to
lower rates of typical antimuscarinic adverse
events [14]. Many participants were receiving
multiple medications for comorbidities, but
sometimes incorrectly attributed other unde-
sirable effects to their OAB medication. The
choice to discontinue the OAB medication over
other treatments may suggest a poor perception
of the benefit–risk balance of available OAB
treatment options, as well as assigning a low
priority to managing OAB.
The findings of the current study are aligned
with the results of a survey from 5392 respon-
dents using antimuscarinic agents for OAB in
the USA [18], among whom 1322 (24.5%)
reported discontinuing one or more antimus-
carinic medications during the previous
12 months. The most commonly reported rea-
sons for discontinuation were that ‘it didn’t
work as expected’ (46.2%), ‘switched to a new
medication’ (25.1%), ‘learned to get by without
medication’ (23.3%), and ‘I had side effects’
(21.1%). A proportion of participants (11%)
indicated a general aversion to taking any
medication. In another US survey of OAB,
among the 138 women who reported that they
had taken or were currently taking OAB medi-
cation, half of them had discontinued OAB
medication at some point; the most common
reasons were inadequate efficacy (42%) and
adverse events/intolerability (30%) [30].
The issue of drug/condition hierarchy was
evident in several participants who opted to
discontinue OAB treatment while prioritising
other conditions, such as hypertension, for
which the consequences of stopping treatment
would be more drastic in their opinion. This
verifies the findings of other studies showing
that rates of persistence and adherence appear
to be particularly low for OAB medications
(specifically antimuscarinic agents) compared
with other chronic conditions, such as diabetes,
glaucoma, hyperlipidaemia, osteoporosis and
hypertension [25].
Better persistence and/or adherence to OAB
medication is associated with improved urinary
symptoms and HRQoL [19, 20]. OAB manage-
ment primarily through coping strategies in
preference to HCP consultation has been high-
lighted in several studies [9, 13, 31]. Similarly,
in the current study, some participants down-
played or normalised their symptoms and
‘learned to live with it’ by employing coping
strategies—these may have a negative impact
on patients’ HRQoL and may also hinder the
realisation of potential clinical benefits from
OAB treatment. This was exemplified by one
participant who had resumed OAB medication
in order to pursue a new hobby.
In the current study, barriers to patients
seeking initial help included a perceived lack of
publicly displayed information on OAB, as well
as a general unawareness of the availability of
treatments. More information may help
patients recognise how widespread such symp-
toms are, leading to less embarrassment in dis-
cussing them and thereby facilitating help-
seeking behaviour. This may also help patients
to decide to pursue better care for their OAB,
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rather than incidentally reporting issues while
visiting the GP for other health concerns. Rais-
ing awareness to the multiple medications
available for OAB may also provide motivation
to pursue alternative treatment. The progressive
use of coping strategies may also prevent
patients from presenting to their HCP by
masking the extent of their condition until the
psychological burden becomes too great or they
have a significant event, such as an inconti-
nence episode in public.
The finding that many participants discon-
tinued treatment because of unmet efficacy/tol-
erability expectations suggests that HCPs might
be able to encourage persistence and/or adher-
ence by fostering realistic expectations about the
onset of efficacy and the extent of benefits
[18, 30]. This could include educating patients
that side effects of medication may manifest
before improvements in symptoms become
apparent, and discussing how side effects could
be managed. Furthermore, realistic treatment
goals could focus on practical factors that are
limiting the patient’s HRQoL, such as attending
more social events or travelling longer distances,
rather than simply focusing on symptoms.
The demeanour of HCPs during consultations
led to participants harbouring doubts of both the
diagnosis and the treatments offered. The per-
ceived disinterest of HCPs to review OAB medi-
cation, alongside participants being reluctant to
chase such reviews, has left a gap in patient care,
leading to poor treatment persistence. HCPs can
support treatment persistence and/or adherence
through: the use of patient-centred communica-
tion with more discussion of critical topics (e.g.
the impactofOAB onHRQoL,and concernsabout
treatment) [32]; involving patients in treatment
decisions; reviewing medicines; communication
with other HCPs involved in the patient’s care
[33]. Treatment ‘cycling’ did not appear to be
widespread in the current study (participant #1
received three OAB medications and was plan-
ning to start a fourth), but as patients may need to
try different treatments to find a suitable one,
regularly scheduled reviews would allow patients
to provide feedback and help optimise their care.
Such reviews could be conducted by nurses or
pharmacists (e.g. the Medicine Use Review ser-
vice), thereby relieving pressure on GPs.
There were a number of strengths associated
with the current study. Interviews were open-
ended and designed to encourage participants
to respond fully in their own words (enabling
the generation of rich information). Addition-
ally, data were collected from participants living
in two regions, in the North West and in the
South of England. The study also had a number
of limitations: invited individuals were prese-
lected by HCPs, thus selecting only those who
had sought healthcare for their OAB (selection
bias); the study was restricted to English lan-
guage speakers only; socio-economic factors
were not considered; the duration of treatment
for OAB medications was not captured; and the
type of medication taken for other conditions
was not formally collected and, therefore, anti-
cholinergic burden may have been a factor
influencing OAB medication-taking behaviour.
In addition to no improvement or deteriora-
tion of health, non-adherence and/or non-per-
sistence may lead to higher economic costs with
respect to wasted medicines and increased
demands for other healthcare resources; eco-
nomic considerations of poor persistence and/or
adherence in OAB could be a feature of future
research. Additional data collection methods (e.g.
focus groups, questionnaires/surveys), which may
provide a more complete picture, could be
employed in future studies. Further work is nee-
ded to investigate the extent to which previously
reported determinants of persistence and/or
adherence, such as female (sex), older age group,
use of extended-release formulations and treat-
ment experience [14], influence OAB medication
persistence and/or adherence. These could take
the form of longitudinal studies following a
patient’s journey through medication taking to
understand their decision-making processes bet-
ter. Drug/condition hierarchy and its effect on
disease management and outcomes is also a
potential area of interest for further investigation.
This is particularly relevant in OAB, where
patients may have other long-term comorbidities.
CONCLUSION
In the current study, the primary reason for
non-adherence and/or discontinuing OAB
Adv Ther
medication, as reported by patients, was per-
ceived poor efficacy/unmet expectations, fol-
lowed by side effects. Patients also showed an
aversion to long-term medication taking and
opted to discontinue OAB treatment, according
low priority to OAB relative to other comor-
bidities. By providing confident diagnoses,
managing expectations of treatment benefit,
educating patients on managing side effects,
and raising awareness of the availability of
multiple treatments, HCPs may be able to sup-
port more adherent and persistent behaviours
among patients with OAB.
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